EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

Cihan Yurdaydin iD, Julia Kahlhöfer iD, Florin Alexandru Caruntu, Kendal Yalcin, Selim Gürel, Ulus S Akarca iD, Kathrin Sprinzl, Hans H Bock iD, Jan-Hendrik Bockmann, George V Papatheodoridis iD, Uta Merle, Münevver Demir iD und 6 weitere

United European Gastroenterology Journal · 2026-02 · 14 (1)

DOI: 10.1002/ueg2.70153 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift United European Gastroenterology Journal, online erschienen am 29.11.2025. Verfasst von Cihan Yurdaydin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology, Koc University Medical School, Istanbul, Turkey. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic, Interferon-alpha, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HepNet Study-House, F. Hoffmann-La Roche, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG‐IFNα with or without tenofovir disoproxil fumarate (TDF).

Methods

We conducted a retrospective follow‐up study of the Hep‐Net‐International‐Delta‐Hepatitis‐Intervention‐Study 2 (HIDIT‐II trial). Patients had received 96 weeks of treatment with either PEG‐IFNα‐2a plus TDF or PEG‐IFNα‐2a alone. Patients were included if they had completed the 96‐week treatment period and had at least one follow‐up visit (PEG‐IFNα‐2a + TDF; n = 51, PEG‐IFNα‐2a alone; n = 56).

Results

Patients who received PEG‐IFNα‐2a + TDF were younger (37 vs. 42 years) and no significant differences were observed in other baseline characteristics between the two treatment arms. A total of 26 patients (24%) developed one or more liver‐related endpoints after a mean time of 8.4 years. The incidence of endpoints was significantly lower in the combination group (14% vs. 34%, p = 0.02). The development of liver‐related endpoints was also associated with non‐response to therapy (HDV RNA and HBsAg), elevated HBV DNA at week 72, and baseline age, cirrhosis, platelets, INR, AST, GGT, bilirubin and albumin according to the Cox regression model.

Conclusions

The long‐term follow‐up of this large randomised clinical trial demonstrates that combination therapy with TDF and virological response to PEG‐IFNα‐2a (undetectable HDV RNA and HBsAg loss) were associated with better clinical outcomes. Trial Registration NCT00932971, EudraCT 2008‐005560‐13

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis D, ChronicInterferon-alphaPolyethylene GlycolsTenofovirAdultFemaleHumansMaleMiddle AgedDNA, ViralDrug Therapy, CombinationFollow-Up StudiesHepatitis Delta VirusRecombinant ProteinsRetrospective StudiesRNA, ViralSustained Virologic ResponseTreatment OutcomeViral Load

Stichwörter der Autor:innen

cirrhosisclinical long‐term outcomehepatitis deltaliver decompensationnucleos(t)ide analoguespegylated interferon alphatherapy

Substanzen

Antiviral AgentsDNA, ViralInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRNA, ViralTenofovir

Autor:innen und Institutionen

  • Department of Gastroenterology & Hepatology, Koc University Medical School, Istanbul, Turkey.
  • Department of Gastroenterology, Hepatology, Infectious Diseases und Endocrinology, Hannover Medical School, Hannover, Germany.
  • HepNet Study-House/ German Liver Foundation, Hannover, Germany.
  • D-SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917), Hannover, Germany.
  • Institutul National de Boli Infectioase "Prof Dr Matei Bals", Bucharest, Romania.
  • Dicle University Medical Faculty, Diyarbakir, Turkey.

ORCID-Profile: Cihan Yurdaydin, Julia Kahlhöfer, Ulus S Akarca, Hans H Bock, George V Papatheodoridis, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke

Förderung

  • HepNet Study-House
  • F. Hoffmann-La Roche
  • Gilead Sciences

Zitieren

APA

Yurdaydin, C., Kahlhöfer, J., Caruntu, F. A., Yalcin, K., Gürel, S., Akarca, U. S., Sprinzl, K., Bock, H. H., Bockmann, J. H., Papatheodoridis, G. V., Merle, U., Demir, M., Hardtke, S., Keskin, O., Idilman, R., Cornberg, M., Wedemeyer, H., & Wranke, A. (2026). Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy. United European Gastroenterology Journal, 14(1). https://doi.org/10.1002/ueg2.70153

Vancouver

Yurdaydin C, Kahlhöfer J, Caruntu FA, Yalcin K, Gürel S, Akarca US, et al. Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy. United European Gastroenterology Journal. 2026;14(1). doi:10.1002/ueg2.70153

BibTeX
@article{Yurdaydin2026,
  author = {Yurdaydin, Cihan and Kahlhöfer, Julia and Caruntu, Florin Alexandru and Yalcin, Kendal and Gürel, Selim and Akarca, Ulus S and Sprinzl, Kathrin and Bock, Hans H and Bockmann, Jan-Hendrik and Papatheodoridis, George V and Merle, Uta and Demir, Münevver and Hardtke, Svenja and Keskin, Onur and Idilman, Ramazan and Cornberg, Markus and Wedemeyer, Heiner and Wranke, Anika},
  title = {Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {1},
  doi = {10.1002/ueg2.70153}
}
Kostenlos starten →